Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Tempest Therapeutics Inc TPST.OQ reported a quarterly adjusted loss of $2.07​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-5.46. The mean expectation of two analysts for the quarter was for a loss of $2.60 per share. Wall Street expected results to range from $-3.23 to $-1.98 per share.

• Reported revenue was zero​; analysts expected zero.

• Tempest Therapeutics Inc's reported EPS for the quarter was a loss of $2.07​.

• The company reported a quarterly loss of $7.87 million.

• Tempest Therapeutics Inc shares had risen by 8.2% this quarter and lost 32.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 25.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Tempest Therapeutics Inc is $9.00, about 18.2% above its last closing price of $7.36

This summary was machine generated from LSEG data August 11 at 09:48 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)